共 50 条
Navigating treatment combinations in small-cell lung cancer
被引:0
|作者:
Li, Ning
[1
]
Wang, Si-Yu
[1
]
机构:
[1] Sun Yat sen Univ, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China
来源:
关键词:
1ST-LINE TREATMENT;
BEVACIZUMAB;
CHEMOTHERAPY;
MULTICENTER;
ETOPOSIDE;
ANLOTINIB;
EFFICACY;
D O I:
10.1038/s41591-024-03255-5
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
The ETER701 trial demonstrates that a four-drug regimen, involving the addition of anti-angiogenesis therapy to immuno-chemotherapy, improves survival outcomes for extensive-stage small-cell lung cancer - but is more indeed better when it comes to treating this intractable disease?
引用
收藏
页码:2731 / 2732
页数:2
相关论文